Related Experiment Video

Updated: Feb 15, 2026

Hyaluronic-Acid Based Hydrogels for 3-Dimensional Culture of Patient-Derived Glioblastoma Cells
08:35

Hyaluronic-Acid Based Hydrogels for 3-Dimensional Culture of Patient-Derived Glioblastoma Cells

Published on: August 24, 2018

13.7K

Cell death-based treatment of glioblastoma

Simone Fulda1,2,3

  • 1Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Komturstr. 3a, 60528, Frankfurt, Germany. simone.fulda@kgu.de.

Cell Death & Disease
|January 27, 2018
PubMed

Insights

Cancer cells evade programmed cell death, promoting tumor growth and therapy resistance. Targeting these cell death pathways offers a promising strategy for novel cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • Cancer cells, including glioblastoma, develop mechanisms to evade programmed cell death for survival.
  • Defects in cell death pathways contribute to tumor formation and resistance to existing cancer therapies.

Purpose of the Study:

  • To highlight the therapeutic potential of targeting cancer cell death pathways.
  • To review strategies for selectively targeting cell death mechanisms in oncology.

Main Methods:

  • Literature review of cell death evasion mechanisms in cancer.
  • Analysis of therapeutic approaches targeting cell death pathways.
  • Examination of clinical applications in oncology.

Main Results:

  • Evasion of cell death is a key hallmark of cancer, enabling survival and treatment resistance.
  • Targeting cell death pathways presents a viable strategy to overcome cancer's resistance mechanisms.
  • Several therapeutic concepts targeting cell death are in clinical development.

Conclusions:

  • Targeting cell death pathways represents a critical approach to combatting cancer.
  • The development of therapies focused on cell death mechanisms offers new perspectives for cancer treatment.
  • Clinical translation of cell death-targeting strategies holds significant promise for oncology.

More Related Videos

A β-glucuronidase GUS Based Cell Death Assay07:35

A β-glucuronidase GUS Based Cell Death Assay

Published on: May 6, 2011

28.8K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K

Related Concept Videos

Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
4.6K
Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
10.3K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
987